CervoMed Inc. Total Liabilities
CervoMed Inc. total liabilities. Based on the latest financial reports, CervoMed Inc. (CRVO) has total liabilities worth $3.03 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CRVO asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CervoMed Inc. (1998–2025)
Total liabilities of CervoMed Inc. from 1998 to 2025. This chart illustrates how CervoMed Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore CervoMed Inc. (CRVO) long-term investment share to see how much of total assets are deployed in long-term investments.
CervoMed Inc. Competitors by Total Liabilities
The table below lists competitors of CervoMed Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DJ Mediaprint & Logistics Limited
NSE:DJML
|
India | Rs365.72 Million |
|
AztechWB Co. Ltd
KQ:032080
|
Korea | ₩10.51 Billion |
|
LANCOR HOLDINGS LTD.
NSE:LANCORHOL
|
India | Rs1.86 Billion |
|
Atlantic American Corporation
NASDAQ:AAME
|
USA | $321.37 Million |
|
SG Choongbang Co Ltd
KO:001380
|
Korea | ₩44.00 Billion |
|
TRF Limited
NSE:TRF
|
India | Rs2.57 Billion |
|
Ayes Celik Hasir ve Cit Sanayi AS
IS:AYES
|
Turkey | TL2.24 Billion |
|
Vection Technologies Ltd
AU:VR1
|
Australia | AU$55.72 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down CervoMed Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CRVO total asset value.
Liquidity & Leverage Metrics
CervoMed Inc. Total Liabilities Ratios Explained
CervoMed Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CervoMed Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CervoMed Inc. (1998–2025)
The table below shows the annual total liabilities of CervoMed Inc. from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.18 Million | +33.44% |
| 2024-12-31 | $3.88 Million | +49.45% |
| 2023-12-31 | $2.60 Million | -80.27% |
| 2022-12-31 | $13.16 Million | +349.35% |
| 2021-12-31 | $2.93 Million | +0.42% |
| 2020-12-31 | $2.92 Million | -29.65% |
| 2019-12-31 | $4.14 Million | +59.98% |
| 2018-12-31 | $2.59 Million | -47.30% |
| 2017-12-31 | $4.92 Million | -40.77% |
| 2016-12-31 | $8.30 Million | +258.02% |
| 2015-12-31 | $2.32 Million | -49.75% |
| 2014-12-31 | $4.61 Million | -61.17% |
| 2013-12-31 | $11.88 Million | -43.03% |
| 2012-12-31 | $20.85 Million | +5.99% |
| 2011-12-31 | $19.68 Million | +254.17% |
| 2010-12-31 | $5.56 Million | +46.60% |
| 2009-12-31 | $3.79 Million | -23.03% |
| 2008-12-31 | $4.92 Million | -35.30% |
| 2007-12-31 | $7.61 Million | +5222.53% |
| 2006-12-31 | $142.96K | +50.70% |
| 2005-12-31 | $94.86K | -99.51% |
| 1999-12-31 | $19.41 Million | +49.31% |
| 1998-12-31 | $13.00 Million | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more